Opinion|Videos|November 17, 2026

PD-L1 and Immunotherapy Selection in Gastrointestinal Cancers

Nicholas Hornstein, MD, PhD, explains that programmed death-ligand 1 (PD-L1) testing plays no role in standard colorectal cancer care, although he requests it for clinical trial eligibility.

Nicholas Hornstein, MD, PhD, explains that programmed death-ligand 1 (PD-L1) testing plays no role in standard colorectal cancer care, although he requests it for clinical trial eligibility. Immunotherapy in colorectal cancer instead relies on microsatellite instability-high (MSI-H) status and a pan-cancer tumor mutational burden (TMB) approval, including a new approval for neoadjuvant dostarlimab in locally advanced rectal cancer. Dr. Hornstein calls TMB testing critical because POLE- and POLD-mutated tumors behave like MSI-H disease. Nicole Balmaceda, MD, notes PD-L1 has no current role in pancreatic cancer and describes combined positive score (CPS) selection in esophagogastric cancer, where CheckMate 649 showed an overall survival benefit for nivolumab plus chemotherapy at a CPS of at least 5 and KEYNOTE-859 showed benefit for pembrolizumab plus chemotherapy at a CPS of at least 1. Dr. Hornstein adds that HERIZON-GEA-01 showed a survival benefit for a human epidermal growth factor receptor 2-directed bispecific antibody plus programmed cell death protein 1 inhibition and chemotherapy, with no PD-L1 cutoff.


Related to this article